Avalo Therapeutics, Inc. (AVTX)
22.98
+1.17
(+5.36%)
USD |
NASDAQ |
May 07, 16:00
22.32
-0.66
(-2.87%)
After-Hours: 07:29
Avalo Therapeutics Free Cash Flow : -51.46M for Dec. 31, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Catalyst Pharmaceuticals, Inc. | 208.61M |
| AbbVie, Inc. | 17.82B |
| Relmada Therapeutics, Inc. | -45.79M |
| Theravance Biopharma, Inc. | 238.50M |
| Corcept Therapeutics, Inc. | 119.79M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -14.25M |
| Cash from Investing (Quarterly) | 2.401M |
| Cash from Financing (Quarterly) | 0.687M |
| Free Cash Flow Per Share (Quarterly) | -0.7695 |
| Free Cash Flow to Equity (Quarterly) | -14.12M |
| Free Cash Flow to Firm (Quarterly) | -14.25M |
| Free Cash Flow Yield | -16.63% |